Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.